IL27670A - Antibiotic compositions containing d-cyclo serine and o-carbamyl-d-serine - Google Patents
Antibiotic compositions containing d-cyclo serine and o-carbamyl-d-serineInfo
- Publication number
- IL27670A IL27670A IL27670A IL2767067A IL27670A IL 27670 A IL27670 A IL 27670A IL 27670 A IL27670 A IL 27670A IL 2767067 A IL2767067 A IL 2767067A IL 27670 A IL27670 A IL 27670A
- Authority
- IL
- Israel
- Prior art keywords
- weeks
- serine
- carbamyl
- cycloserine
- pigs
- Prior art date
Links
- MYFVWSDZEBSNKM-UWTATZPHSA-N (2r)-2-amino-3-carbamoyloxypropanoic acid Chemical compound OC(=O)[C@H](N)COC(N)=O MYFVWSDZEBSNKM-UWTATZPHSA-N 0.000 title claims description 36
- 239000000203 mixture Substances 0.000 title claims description 30
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 title claims description 20
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 title claims description 20
- 230000003115 biocidal effect Effects 0.000 title claims description 17
- 108010001478 Bacitracin Proteins 0.000 claims description 46
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 19
- 229960003077 cycloserine Drugs 0.000 claims description 18
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 235000019730 animal feed additive Nutrition 0.000 claims description 2
- 230000003389 potentiating effect Effects 0.000 claims 3
- 241000282887 Suidae Species 0.000 description 39
- 238000012360 testing method Methods 0.000 description 24
- 241000282898 Sus scrofa Species 0.000 description 15
- 229960003071 bacitracin Drugs 0.000 description 12
- 229930184125 bacitracin Natural products 0.000 description 12
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 12
- 206010039083 rhinitis Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 206010035664 Pneumonia Diseases 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 229940049954 penicillin Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- 239000004182 Tylosin Substances 0.000 description 5
- 229930194936 Tylosin Natural products 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 5
- 229960000973 sulfadimethoxine Drugs 0.000 description 5
- 229960004059 tylosin Drugs 0.000 description 5
- 235000019375 tylosin Nutrition 0.000 description 5
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 5
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 4
- -1 50 grams Chemical compound 0.000 description 4
- 238000011887 Necropsy Methods 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- 235000014590 basal diet Nutrition 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 206010008631 Cholera Diseases 0.000 description 3
- 201000000297 Erysipelas Diseases 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 239000004100 Oxytetracycline Substances 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 235000013405 beer Nutrition 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 229960000625 oxytetracycline Drugs 0.000 description 3
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 3
- 235000019366 oxytetracycline Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 3
- POMORUSPLDFVEK-PHXAWWDYSA-N (4r)-5-[[(2s,3s)-1-[[(2s)-6-amino-1-[[(2r)-5-amino-1-[[(2s,3s)-1-[[(2r)-1-[[(2s)-1-[[(2r)-1-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methy Chemical compound OC1=CC=CC=C1C(=O)OCOC(=O)C1=CC=CC=C1O.C1SC(C(N)C(C)CC)=NC1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 POMORUSPLDFVEK-PHXAWWDYSA-N 0.000 description 2
- 235000019783 Bacitracin Methylene Disalicylate Nutrition 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000004099 Chlortetracycline Substances 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 229940032022 bacitracin methylene disalicylate Drugs 0.000 description 2
- 108010054309 bacitracin methylenedisalicylic acid Proteins 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002135 sulfadimidine Drugs 0.000 description 2
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 description 2
- 229960004936 sulfamethoxypyridazine Drugs 0.000 description 2
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229960001544 sulfathiazole Drugs 0.000 description 2
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001944 turbinate Anatomy 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 206010004016 Bacterial diarrhoea Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187389 Streptomyces lavendulae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
Description
27670/2
Antibiotic coapoaitione coatainitie I» cyclo serine and O-carbamyl-D-serine
This invention relates to new compositions useful in veterinary medicines and as animal feed additives and more particularly to a new composition containing as its essential ingredients an i/v antibiotic such as bacitracin in combination with teycloserine and
- O-carbamyl-D-serine.
One important trend in modern production of marketable animals, e.g., poultry, swine, cattle, sheep, etc, , is toward a more rapid development of market-weight animals. Thus the amount of time in which equipment, space, and feed are occupied in grow-0 ing the animal to a marketable size is of importance as is the amount of consumed feed, i.e., feed efficiency. An increased feed efficiency results in less cost in producing market-weight animals β
It is known that various antibiotics promote growth and increase feed efficiency of animals. Such antibiotics include bacitracin, neomycin, penicillin, the tetracyclines, the sulfa drugs, tylosin, chloramphenicol, erythromycin, and o!hers. At different dosage levels, these antibiotics also are effective therapeutic agents for various bacterial infections in animals. For example, bacitracin is effective in the prevention of bacter-0 ial swine enteritis , oxytetracycline is effective in the treatment of bacterial diarrhea in sheep and other animals and the other antibiotics are effective against these or other bacterial infections.
It has now been surprisingly discovered that the pharmacological activity in animals of these antibiotics is potentiated by an admixture of^cycloserine and 0-carbamyl,-D-serine. Cycloserine itself is an antibiotic active against many gram-negative and gram- positive microorganisms. It is produced during the cultivation of a particular strain of Streptomyces lavendulae and is described in 0 U. S, patent 2 ,773,878. O-carbamyl-D-se'rine , described in U, S. patent 2,885,133, is also known as a therapeutic agent in veteri-
nary medicine.
The potentiation of the pharmacological activity of the
/ antibiotics is due to the admixture of/ cycloserine and O-carbamyl- D-serineβ Data show that the growth activity of the antibiotic is not improved when either cycloserine or O-carbamyl-D-serine alone are administered with the antibiotic in amounts equivalent to
those of the three component mixtures. The activity of the ad- /< mixture of cycloserine and O-carbamyl-D-serine with the antibiotic also surpasses the separate activity of equivalent amounts of the 0 individual constituents of the mixture»
D- Antibiotics which are potentiated by an admixture of/cycloserine and O-carbamyl-D-serine include neomycin; bacitracin, including the active salts of bacitracin such as zinc bacitracin, manganese bacitracin and bacitracin methylenedisalicylate , feed grade bacitracin and bacitracin-containing materials such as the dried bacitracin-containing whole beer remaining after separation of bacitracin from fermentation media in which it is produced;
penicillin, iaea , from procaine penicillin; the tetracyclines, including tetracycline, chlortetracycline and oxytetracycline ; 0 tylosin; chloramphenicol; erythromycin; and sulfa drugs, including sulfanilamidoquinoxaline , sulfamethoxypyridazine, sulfathiazol , sulfanilamide, sulfamethazine, and sulfadimethoxine ; alone or in combination or in combinations with other materials common to feed additives such as described in the Feed Additive Compendium issued February, 1966, by the Miller Publishing Company,,
The amount of antibiotic and admixture of O-carbamyl-D- _ serine and/cycloserine administered is an effective amount, that is, an amount sufficient to produce a pharmacological effect such as to improve the rate of growth and the feed efficiency of the 0 animal, or a therapeutic amount for the particular disorder. The exact amount of the dosage will vary depending upon the particular
antibiotic, the intended use, the ratio of O-carbamyl-D-serine
/cyclos used, the body weight of the subject, the method used in administering the dose to the subject, and whether single or multiple dosages are contemplated^ The weight ratio of antibiotic to admixture of^cycloserine and O-carbamyl-D-serine will generally fall in the range of about 1:1 to 1:9, preferably about 1:2 to 1:6» The weight ratio of O-carbamyl-D-serine to/ cycloserine in the admixture will usually fall in the range of about 20:1 to 1:4, preferably about 12:1.to 1:2, Ordinarily the dosage of the composition orally administered falls in the range of about 1 to 700 milligrams, preferably 60 to 500 milligrams per kilogram body weight of the animal per day. The antibiotic is ordinarily administered to the animal as a dosage unit comprising from about 1 to 100 grams, preferably 2 to 50 grams of the antibiotic, per ton of feed, i„e., nutrient ration such as a basal feed, as a carrier.
The composition of the invention can also be orally
ministered in vehicles well known to the art, for instance, in solution in water, alcohol, oils, syrups, and suspending agents, eeg. , gum arabic or similar polysaccharides „ Alternatively, the composition may be given with solid carriers which can be any palatable foodstuffs such as sugar, sweetened starch compositions and the like. The compositions can be in pill, paste, capsule or tablet form, which can be covered with a sweetened or flavored edible coating, if desiredo In addition to oral administration, the composition of this invention may be administered by any other suitable method including parenteral administration „ For example, the composition may be suspended in a suitable injection suspension such as peanut oil and injected parenterally „
The following examples illustrate the invention, but are not to be considered limiting. Example I illustrates the
potentiation of zi .nc baci.traci.n by a mi.xture of/pc-ycloserine and
O-carbamyl-D-serine when treating healthy swine,
EXAMPLE I
Two litters (16) of apparently healthy, well doing pigs were obtained, weaned at 8 weeks, ear-notched, vaccinated for cholera and erysipelas and allocated to two test groups on an equalized weight and sex basis0 Individual weights and group fe consumption were recorded every two weeks. The two treatment groups were a control group and a test group of eight pigs each. The control group was fed the basal ration of Table I in self-feeders. The test group was fed the basal ration mixed with an admixture of 50 grams of zinc bacitracin and 200 grams of/cyclo- i
serine ( CS ) and O-carbamyl-D-serine (OCS) in a weight ratio of CS:0CS of 1:3, The zinc bacitracin employed was the product obtained by drying the beer remaining following precipitation of zinc bacitracin from fermentation media containing the same and contained 10 grams of zinc bacitracin per pound,
TABLE I
Ground Yellow Corn 795 lb.
Soybean Oil Meal-50% 180 lb.
Ground Limestone 10 lb.
Di Calcium Phosphate 10 lb.
Iodized Salt 5 lb„
Trace Mineral Mix 227 gm.
Vitamin A (30,000 IU/gm. ) 50 gm.
Vitamin D2 (75,000,000 IU/gm,) 0,75 gm.
BY-24 16, d gm.
Calcium Pantothenate 5,6 gm.
Niacin 98% 8,0 gm.
Choline Chloride 25% 200,0 gm.
Proferm 12 302 , 0 gm.
1,001, 8 lb.
The addition of zinc bacitracin and CS:OCS to the basal ration of healthy pigs produced a 32% increase in average daily gain over the controls which gained at a rate of 1.51 pounds per day. The results are summarized in Table II.
TABLE II
Zinc Bacitracin
Basal CS ;0CS
No, Pigs 8 8
Av, Initial wt, (Lbs.) 38,4 38.9 Av, Final wt. (Lbs.) 166.9 207.7 Days on test 85 85
Av, Daily Gain (Lbs.)
0-1 week 1.14 1.07
1- 3 weeks 1.35 1.68
3-5 weeks 1,20 1.90
-7 weeks 1.81 2.24
7- 8 weeks 2.00 2, 62
8-10 weeks 1,43 2,26 10-12 weeks 1.73 2.05
0-12 weeks 1.51 1.99
Lbs, Feed/Lb. Gain
0-12 weeks 2.98 3.13
The following example illustrates the effect of zinc bacitracin and OCS alone and in combination on growth and feed efficiency in swine.
EXAMPLE II
Forty weanling pigs, 6 to 7 weeks of age and averaging 24 pounds, were allocated to four test groups on an equalized
weight basis. All pigs were vaccinated for cholera and erysipelas at the start of the test. They were wormed with piperazine in the water after 6 weeks on test, Individual weights and group feed consumption were recorded every two weeks , Treatment groups included zinc bacitracin at 50 grams per ton, a mixture per ton of zinc bacitracin, 50 grams, and OCS, 200 grams, and OCS at 250 grams/ ton, The zinc bacitracin was that employed in Example I. The basal ration of Table I was used to prepare the feeds,, Test
period was 8 weeks.
No growth response was obtained from any of the treatments, A slight (6%) improvement in feed conversion was evident in the group receiving zinc bacitracin alone, The combination of zinc bacitracin and OCS or OCS alone was not effective in promoting growth and zinc bacitracin alone produced improvement only in feed efficiency and not in gain. The test results are summarized in Table III,
Basal Zinc Bacitracin + OCS Zin
No, of Pigs 10 10
Av, Initial Wt, (Lbs,) 23,9 23,7
Av, Final Wto (Lbs,) 98,6 97,3
Days on Test 56 56
Av. Daily Gain (Lbs,)
0-2 weeks 0„92 0,96
2-4 weeks 1,23 1,18
4-6 weeks 1,50 1,43
6-8 weeks 1,68 1,68
0-8 weeks 1,33 1, 31 ± ,18
Lbs, Feed/Lb, Gain
0-2 weeks 1,84 1,72
2-4 weeks 2.38 2,50
4-6 weeks 2,49 2,52
6-8 weeks 2,81 2,70
0-8 weeks 2,45 2,43
The following example illustrates the efficacy of an admixture of zinc bacitracin, CS and OCS in treating swine affected with rhinitis and virus pneumonia,
EXAMPLE III
Ten weanling pigs were procured from a herd having a high incidence of rhinitis and virus pneumonia,, Each pig was ear-notched, weighed and started on a basal diet for three days0 Fecal samples were checked, ascarid eggs identified, and the pigs were wormed with piperazine in water. After three days the pigs were reweighed and allocated on an equalized weight basis into a basal and a treatment group of five pigs each. Feed and water were supplied ad-libitum» The pigs were weighed individually every two weeks, and feed consumption was recorded. The treatment group received the basal ration mixed with per ton of ration an admixture of 50 grams of zinc bacitracin and 200 grams CS:0CS (1:3)» The zinc bacitracin was that employed in Example I. Test period was nine weeks.
The addition of the admixture of zinc bacitracin, CS and OCS to the ration of Table I resulted in a 33% improvement in daily gain and a 7% improvement in feed efficiency during the nine week test period as summarized in Table IV„
TABLE IV
Basal Zinc Bacitracin + CS:0CS
No, Pigs 5 5
Av, Initial wt, (Lbs,) 13,5 13,7
Avo Final wt0 (Lbs0) 55,4 69,2
Days on Test 63 63
Av, Daily Gain (Lbs,)
0-2 weeks ,20 o 32
2-4 weeks ,67 o 79
4-6 weeks ,62 , 77
6-8 weeks 068 1.21
8-9 weeks 1, 08 1,74
0-9 weeks «,66 , 88
Lbs, Feed/Lb, Gain
0-2 weeks 3.09 3 18
2-4 weeks 2 „ 05 1 96
4-6 weeks 3,12 2 99
6-8 weeks 2,72 2 49
8-9 weeks 2,49 2 19
0-9 weeks 2,64 2 47
At completion of the test the treated group was fed the basal diet for 48 hours and then all pigs were necropsied.
Necropsy revealed extensive lung damage in all basal fed animals with evidence of active pneumonic lesions , Treatment pigs showed evidence of early infection and healed lesions with no active areas present. Nasal turbinates were extensively damaged or nonexistent in most all pigs,
The following example illustrates the effect of zinc bacitracin and CS:0CS alone and in combination in pigs affected with rhinitis and virus pneumonia,,
EXAMPLE IV
Forty weanling pigs were obtained from a herd of swine having a high incidence of rhinitis and virus pneumonia. They were ear-notched, weighed and allocated to four treatment groups of 10 pigs each on an equalized weight basiso Individual weights and group feed consumption were recorded every two weeks. After two weeks all pigs were wormed with piperazine in the water and
vaccinated for cholera and erysipelas. All pigs were fed basal diet for 48 hours before the completion of the test and the final weigh period. The four treatment groups were (1) fed the basal ration of Table I as a control; (2) the basal ration, zinc
bacitracin, CS , OCS feed mixture of Example I; (3) zinc bacitracin in the amount of 250 grams per ton of the basal ration of Table I; and (4) the basal ration of Table I admixed with 250 grams per ton of ration of a mixture of CS and OCS in a weight ratio of CS:0CS of 1:3, The test period was 12 weeks.
The combination of zinc bacitracin and CS:0CS produced a 21% increase in average daily gain over the 12 week period. Zinc bacitracin alone or CS:0CS alone gave no response. The test re-suits are set forth in Table V,
Control Zinc bacitracin + CS:0CS Zinc
No. Pigs 8 9
Av. Initial Wt, (Lbs0) 15.3 14.7
Av, Final Wt. (Lbs, ) 84, 6 100, 7
Days on Test 84 84
, Daily Gain (Lbs,)
0-2 weeks .31 54
2-4 weeks ,30 47
4-6 weeks ,72 75
6-8 weeks 1,02 21
8-10 weeks 1,25 54
-12 weeks 1,24 34
0-12 weeks ,82 99
Lbs. Feed/Lb, Gain
0-2 weeks 2 77 06
2-4 weeks 3 49 05
4-6 weeks 2 65 10
6-8 weeks 2 51 29
8-10 weeks 2 64 49
-12 weeks 2 94 24
0-12 weeks 2 76 70
Five pigs from each treatment group were necropsied? At necropsy all pigs showed evidence of rhinitis and virus pneumonia to varying degrees,
The following example illustrates the effect of CSsOCS on growth promotion and feed efficiency in swine with rhinitis-virus pneumoniae
EXAMPLE V
Thirteen weanling pigs obtained from a herd severely affected with rhinitis and virus pneumonia were allotted to weight equalized basal and treatment groups of six and seven pigs respectively and fed and watered ad-libitum. Pigs were weighed individually every two weeks and feed consumption was recorded, The treatment group received the basal ration of Table I with CSsOCS (Is 3) admixed therewith in the amount of 250 grams per ton. The test period was eight weeks, CS:0CS (1:3) added to the ration had no effect on rate of gain or feed efficiency of pigs affected with rhinitis and virus pneumonia. Two very poor pigs receiving CSsOCS lived through the test period while a similar pig in the basal group died. Analysis of variance of the data show no significance nor is there any percentage difference, CS:0CS (1:3) alone is not effective in promoting growth in pigs with rhinitis and virus pneumonia.
TABLE VI
BASAL
No, Pigs 5
Av, Initial wt, (Lbs,) 16 o 6
Av. Final wt, (Lbs,) 82 , 6
Days on Test 56
Av. Daily Gain (Lbs,)
0-2 weeks o 72
2-4 weeks , 91
4-6 weeks 1, 35
6-8 weeks lo 63
0-8 weeks 1, 13
, Feed/Lb, Gain
0-2 weeks 1, 95
2—- weeks 2 , 23
4-6 weeks 2 o 27
6-8 weeks 2 , 22
0-8 weeks 2 , 18
'"'Figures in parenthesis are those obtained when two small pigs are compensate for similar pigs in the control group which died.
At the completion of the test the CS:OCS group received basal diet for 48 hours prior to necropsy,, Necropsy revealed only moderate damage to the turbinates and lungs of the pigs in both groups o
The following example illustrates the efficacy of an admixture of CS , OCS, sulfadimethoxine and zinc bacitracin in swine from a herd infected with rhinitis-virus pneumonia,
EXAMPLE VI
The test compared two groups of five pigs each allocated on an equalized weight basis, one of the groups receiving the basal ration of Table I and the other group receiving the basal ration having admixed therewith per ton of ration an admixture of 50 grams zinc bacitracin, 50 grams CS and OCS at a CS:0CS ratio of 1:3, and 100 grams sulfadimethoxine „ All pigs were affected with rhinitis and virus pneumonia. The pigs were fed ad-libitum, were weighed individually every two weeks , and feed consumption for each group was recorded at the weigh period..
The addition of the zinc bacitracin, CS , OCS and sulfa-dimethoxine admixture to the normal basal ration improved the growth rate for six weeks by 14% and the feed efficiency by 7% in pigs affected with rhinitis and virus pneumoniae
Bac,-CS:OC
Basal Sulfa
Daily Gain ( Lbs , )
0-2 weeks .73 1.08
2-4 weeks 1.08 1.26
4-6 weeks 1.42 1, 35
0-6 weeks 1,08 1.23
o Feed/Lb, Gain
0-2 weeks 3.11 67
2-4 weeks 2.93 33
4-6 weeks 2,28 52
0-6 weeks 2,69 50
Avo Initial t. (Lbs,) 43.4 42,7* ( Av, Final wt, (Lbs,) 88,6 98,7 Days on Test 42 42 No0 Pigs 5 4
*0ne pig died of pneumonia after 4 weeks, —Final weight on four pi
EXAMPLE VII
Four separate 2 0 0 gram batches of a mixture of CS2OCS in weight ratios of 1 : 9 , 1 : 1 and 3 : 1 , respectively, each batch admixed with 5 0 grams of the zinc bacitracin of Example I are prepared and each of the four admixtures is separately admixed with a ton of the basal ration of Table I„ Each feed admixture is administered to swine „ The rate of growth and feed conversion of the swine are improved. The improvement is noted with healthy swine as well as diseased swine,
EXAMPLE VIII
A two hundred gram batch of a mixture of CSsOCS in a
1 : 3 weight ratio is separately admixed with fifty grams of each of the following antibiotics: bacitracin; manganese bacitracin; bacitracin-methylene disalicylate ; neomycin; tylosin; penicillin (from procaine penicillin); tetracycline; oxytetracycline ;
chlortetracycline ; chloramphenicol; erythromycin; sulfamethazine; sulfanilamide; sulfamethoxypyridazine ; sulfathiazole ; sulfanil-amidoquinoxaline ; sulfadimethoxine ; zinc bacitracin admixed with penicillin (from procaine penicillin) (containing between 5 0 and 7 5 % zinc bacitracin); tylosin admixed with penicillin (from procaine penicillin) ( 1 „ 2 parts penicillin to 2 parts tylosin); and chlortetracycline-sulfamethazine-penicillin in a weight ratio of l:l: 0 o 5 o Each admixture is separately admixed with a ton of the basal ration of Table I»
EXAMPLE IX
The antibiotic admixtures with CS and OCS of Examples VII and VIII are admixed with nutritionally adequate rations for chickens, turkeys, sheep and cattle and administered as feedo
The rate of growth and feed conversion of the animals is improved, This improvement is noted with healthy animals as well as diseased animals
The /cycloserine and O-carbamy1-D-serine employed in the above examples were high potency pharmaceutical grade products „
D- Other less pure forms of/cycloserine and O-carbamyl-D-serine can be employed, however, such as the dried crude/ cycloserine whole beer, or the dried crude /cycloserme-containmg broth obtained after filtration of the mycelium from the fermenter effluent described in U o S c patent No, 2 , 7 7 3 , 8 7 8 , or the corresponding dried O-carbamyl-D-serine containing filtrate described in U „ S o patent oo 2 , 8 8 5 , 4 3 3 ο In any event, the antibiotic-¾ycloserine-O-carbamyl-D-serine admixture should be maintained as dry as possible to preserve its potency and when admixed with
nutritionally adequate rations, the rations should have low water content, i.e., below about 10% by weight of water, advantageously below about 5 % by weight of water- By the term "antibiotic" is meant any drug intended for use by man containing any quantity of any chemical substance which is produced by a micro-organism and which has the capacity to inhibit or destroy microorganisms in dilute solution (including the chemically synthesized equivalent of any such substance) and in addition the term is construed to include those materials having chemotherapeutic activity, such as the sulfa drugs, normally employed in animal nutrition or animal disease therapy „
Claims (2)
- HAVING NOW particularly described ?Jid ascertained the nati of our said invention and in what manner the same is to be performed^ we declare that what we claim ist The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows : 1» A composition comprising an admixture of an antibiotic ^ 1 other than a/c-ycloseri .ne or O-carbamyl-D-serm . e and an anti .bi.oti.c ,D- ^ . potentiating amount of a mixture of/ cycloserine and O-carbamyl-D- serine .
- 2. A composition comprising an admixture of at least one , , animal feed additive antibiotic other than /cycloserine or O-carbamyl- D-serine and an antibiotic potentiating amount of a mixture of D- cycloserine and O-carbamyl-D-serine; the weight ratio O-carbamyl- D-serine toD//c-ycloserine being within the range of about 20 :1 to 1:4. 3o The composition of claim 2 wherein the weight ratio of Ί O-carbamyl-D-serine to/cycloserine is within the range of about 12 :1 to 1:2. 4» A composition comprising zinc bacitracin and a potentiat- /D- j rj mg amount of a mixture of/cycloserine and O-carbamyl-D-serme . 5<, A composition comprising zinc bacitracin and a potentiat- - ing amount of a mixture of/cycloserine and O-carbamyl-D-serine , the weight ratio of O-carbamyl-D-serine to cycloserine being within the range of about 20 :1 to 1:4» 6, The composition of claim 5 wherein the weight ratio of Dr . . . O-carbamyl-D-serine to/cycloserine is within the range of about 12 :1 to 1.2. 7o A method for improving the rate of growth and feed conversion of animals comprising administering to said animals an amount of the compositions of claim 1 effective to improve the rate of growth and feed conversion. 8a A method for improving the rate of growth and feed conversion of animals comprising administering to said animals an amount of the two- composition^ of claim 4 effective to improve the rate of rowth and feed conversion,,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54482166A | 1966-04-25 | 1966-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL27670A true IL27670A (en) | 1970-09-17 |
Family
ID=24173734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL27670A IL27670A (en) | 1966-04-25 | 1967-03-23 | Antibiotic compositions containing d-cyclo serine and o-carbamyl-d-serine |
Country Status (4)
| Country | Link |
|---|---|
| BE (1) | BE697502A (en) |
| DE (1) | DE1692410A1 (en) |
| GB (1) | GB1134788A (en) |
| IL (1) | IL27670A (en) |
-
1967
- 1967-03-22 GB GB13440/67A patent/GB1134788A/en not_active Expired
- 1967-03-23 IL IL27670A patent/IL27670A/en unknown
- 1967-04-18 DE DE19671692410 patent/DE1692410A1/en active Pending
- 1967-04-24 BE BE697502D patent/BE697502A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB1134788A (en) | 1968-11-27 |
| DE1692410A1 (en) | 1971-07-29 |
| BE697502A (en) | 1967-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0195906A2 (en) | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties | |
| Atkinson et al. | Vitamin B12, an APF concentrate, aureomycin, streptomycin, Liver “L” and fish meal and fish solubles in the nutrition of the poult | |
| EP1143805B1 (en) | Method for reducing incidence of ascites in poultry by aid of natamycin | |
| JPS6114124B2 (en) | ||
| IL27670A (en) | Antibiotic compositions containing d-cyclo serine and o-carbamyl-d-serine | |
| US4237116A (en) | Combination of thiopeptin and rumensin to improve ruminant feed efficiency | |
| US3085936A (en) | Gastro-enteritis-diarrheal syndrome treatment | |
| US3790669A (en) | Synergistic tylosin and furazolidone medication for calf pneumoenteritis complex | |
| US3178343A (en) | Pharmaceutical compositions and method of using same | |
| DE69321554T2 (en) | Antibiotic mixture of gentamicin with lincomycin-containing veterinary preparation as an additive for drinking water or animal feed and its use in the rearing of pigs | |
| US5081146A (en) | Method and feed supplement for the feeding of ruminants | |
| US3655882A (en) | Stable dietary supplement for new born pigs | |
| US4283388A (en) | Method for treating colibacillosis in pigs with tylosin apramycin compositions | |
| US3868456A (en) | Certain hydantoins having animal growth stimulating activity | |
| GB1583155A (en) | Rearing of animals | |
| US3497594A (en) | Combinations of quinoxaline-di-n-oxides and tetracycline antibiotics | |
| US3531568A (en) | Medicated poultry drinking composition comprising a tetracycline antibiotic and a sulfate compound and the use thereof | |
| US4124626A (en) | Control of swine dysentery with AV290 and salts or complexes thereof | |
| US3923983A (en) | Medicated poultry composition and method employing certain sulfate compounds | |
| CA1059910A (en) | Control of lactic acidosis in ruminants | |
| EP3838347B1 (en) | Evernimicin for treating diseases like necrotic enteritis | |
| US4060614A (en) | 6-Substituted 3-nitroimidazo[1,2-b]pyridazine for the control of hemorrhagic colitis in swine | |
| US3816630A (en) | Treatment of swine dysentery | |
| US3737546A (en) | Use of ipronidazole in combatting swine dysentery | |
| US4123522A (en) | Control of bloat in ruminants |